SEL-212
Selecta Biosciences
[]
selecta biosciences announces presentation of data from phase 3 dissolve program of sel-212 in chronic refractory gout during late-breaking session at the eular 2023 european congress of rheumatology - health stocks hub $selb 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2